A search for new 5-HT(1A)/5-HT(2A) receptor ligands. In vitro and in vivo studies of 1-[ω-(4-aryl-1-piperazinyl)alkyl]indolin-2(1H)-ones

Archiv der Pharmazie

Volumn 331, Issue 10, 1998, Pages 325-330

  Mokrosz, Maria J ^a   Duszyńska, Beata ^a   Misztal, Stanisław ^a   Kłodzińska, Aleksandra ^a   Tatarczyńska, Ewa ^a   Chojnacka Wójcik, Ewa ^a   Dziedzicka Wasylewska, Marta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT(1A) 5 HT(2A); 5 HT(1A) 5 HT(2A) receptor ligands; Antagonistic in vivo activity; Indolin 1(2H) ones

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYL]INDOLIN 2 ONE; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL]PROPYL] 6 FLUOROINDOLIN 2 ONE; INDOLE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SYNTHESIS; EVOKED RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM;

ANIMALS; BEHAVIOR, ANIMAL; INDOLES; LIGANDS; MALE; MICE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGENTS;

EID: 0344333471     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4184(199810)331:10<325::AID-ARDP325>3.0.CO;2-6     Document Type: Article

References (15)

1. A. Albinsson, A. Björk, J. Svartengren, T. Klint, G. Andersson, Eur. J. Pharmacol. 1994, 261, 285-294.
2. 1C/2 antagonist, potential anxiolytic agents. In: M. Hamon, H. Olat, M.H. Thiebot, eds. Anxiety: Neurobiology, clinic and therapeutic perspectives. Paris: Le éditions INSERM/John Libbey Eurotext. 1993, 153-164.
3. Serotonin Drug Status Update; in Serotonin ID Research Alert 2 1997, 131-141.
4. M. J. Mokrosz, J. L. Mokrosz, B. Duszyńska, A. Dereń-Wesołek, A. Kłodzińska, P. Kowalski, S. Charakchieva-Minol, E. Tatarczyńska, T. Kowalska, Z. Majka, E. Chojnacka-Wójcik, S. Misztal, Pharmazie, 1997, 52, 423-428.
5. G. J. Quallich, P. M. Morrisey, Synthesis, 1993, 51-53.
6. R. D. Clark, J. M. Muchowski, L. E. Fisher, L. A. Flippin, D. B. Repke, M. Souchet, Synthesis, 1991, 871-877.
7. A. J. Bojarski, M. T. Cegła, S. Charakchieva-Minol, M. J. Mokrosz, M. Maækowiak, S. Misztal, J. L. Mokrosz. Pharmazie, 1993, 48, 289-294.
8. H. H. G. Berendsen, F. Jenk, C. L. E. Broekkamp, Pharmacol. Biochem. Behav., 1989, 33, 821-827.
9. M. D. Tricklebank, C. Forler, J. R. Fozard, Eur. J. Pharmacol. 1984, 106, 271-282.
10. N. A. Darmani, B. R. Martin, U. Poandey, R. A. Glennon, Pharmacol. Biochem. Behav. 1990, 36, 901-906.
11. J. Maj, E. Chojnacka-Wójcik, E. Tatarczyńska, A. Kłodzińska, J. Neural. Trans. 1987, 70, 1-17.
12. L. M. Smith, S. J. Peroutka, Pharmacol. Biochem. Behavior. 1986, 24, 1513-1519.
13. M. J. Mokrosz, E. Chojnacka-Wójcik, E. Tatarczyńska, A. Kłodzińska, M. Filip, J. Boksa, S. Charakchieva-Minol, J. L. Mokrosz, Med. Chem. Res. 1994, 4, 161-169.
14. E. Przegaliński, A. M. Ismaiel, E. Chojnacka-Wójcik, B. Budziszewska, E.. Tatarczyńska, E. Błaszczyńska, Neuropharmacology 1990, 29, 521-526.
15. N. A. Moore, G. Rees, G. Sanger, L. Perrett, Pharmacol. Biochem. Behav. 1993, 46, 141-143.